TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker. This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril<a href="https://solaci.org/en/2023/12/19/myval-a-tavr-balloon-expandable-valve-with-promising-results/" title="Read more" >...</a>
Currently, we observe an increase in the number of transcatheter aortic valve replacement (TAVR) procedures due to its expansion toward a younger population with lower risk. For this reason, it is crucial to maintain continuous technological innovation to minimize post-procedural complications. The FDA has approved the SavyWire, a preformed 0.035-caliber guidewire that offers three essential<a href="https://solaci.org/en/2023/12/14/safe-tavi-study-safety-and-efficacy-of-the-pressure-sensor-and-pacing-guidewire/" title="Read more" >...</a>
The progression of aortic stenosis has been extensively studied and is well-known. As observed, in its advanced stages, this condition entails high morbidity and a marked decrease in survival. Both North American and European guidelines recommend treatment when faced with severe valve disease. However, true severity can be difficult to determine due to discordant data,<a href="https://solaci.org/en/2023/11/13/untreated-aortic-stenosis-associated-mortality-and-a-call-to-attention/" title="Read more" >...</a>
The presence of cardiogenic shock (CS) in a setting of aortic stenosis ranges from 1% to 4%. The prognosis for this scenario is ominous due to subendocardial ischemia, which presents as a decrease in ventricular preload and an increase in afterload. Aortic valvuloplasty has been used in this context, but, unfortunately, it has been associated<a href="https://solaci.org/en/2023/11/09/is-tavr-beneficial-in-cardiogenic-shock/" title="Read more" >...</a>
Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status. Tricuspid edge-to-edge repair (T-TEER) with TriClip effectively reduces TR with low risk of post-procedural complications. The TRILUMINATE Pivotal trial (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve<a href="https://solaci.org/en/2023/10/31/tct-2023-triluminate-trial-health-status-after-triclip/" title="Read more" >...</a>
High-risk pulmonary embolism (HR-PE) is characterized by hemodynamic instability and marked deformation of the right ventricular (RV) fiber, which can lead to acute RV failure and hemodynamic collapse, with in-hospital mortality close to 25%. While guidelines recommend anticoagulant treatment followed by thrombolytics, these strategy carries a high risk of bleeding and is not suitable for<a href="https://solaci.org/en/2023/10/24/flame-study-flowtriever-device-in-high-risk-pulmonary-embolism/" title="Read more" >...</a>
Severe tricuspid regurgitation (TR) is an underestimated condition in healthcare systems. However, it is more common than believed, especially in individuals over 65 years of age. This condition is linked to hospitalizations due to heart failure, mortality rates, and a progressive decline in quality of life. Surgery to treat TR on its own is complicated,<a href="https://solaci.org/en/2023/10/04/triclip-good-outcomes-after-a-2-year-follow-up/" title="Read more" >...</a>
The program MIL Training More MIL continues in specialized centers in Buenos Aires. Yesterday it took place at the prestigious Favaloro Foundation. During the session, Dr. Fava, interventional cardiologist from the foundation, delivered talks together with the grant holding physicians on MItraclip, Evidence in Cusp Overlap, Pacemaker Risks in Self-Expandable TAVR, Coronary Artery Disease and<a href="https://solaci.org/en/2023/10/02/mil-training-more-mil-day-4-favaloro-foundation/" title="Read more" >...</a>
Tricuspid valve regurgitation is more common than one might think. It often stems from left valve disease and associated with increased mortality and hospitalization due to heart failure, which is not easy to treat. Currently, guidelines list surgery as the recommended treatment, though this option is quite complex and might entail complications and mortality risk.<a href="https://solaci.org/en/2023/09/19/triluminate-two-years-in-encouraging-results/" title="Read more" >...</a>
The clinical importance of severe tricuspid regurgitation (TR) has been underestimated for many years now. However, studies and registries have shown that, when left untreated, this pathology significantly increases morbidity and mortality. Patients in need of treatment are often older individuals with higher surgical risk due to the prevalence of this condition. Contemporary data has<a href="https://solaci.org/en/2023/08/14/bright-impact-and-safety-of-the-triclip-device-in-a-real-world-cohort/" title="Read more" >...</a>